Brief: Bayer AG - China's Center Of Drug Evaluation Accepts Marketing Authorization Application For Asundexian
April 29 (Reuters) - Bayer AG BAYGn.DE: BAYER AG - CHINA'S CENTER OF DRUG EVALUATION ACCEPTS MARKETING AUTHORIZATION APPLICATION FOR ASUNDEXIAN IN STROKE PREVENTION AFTER A NON-CARDIOEMBOLIC ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK Further company coverage: [BAYGn.DE] (Gdansk Newsroom) (((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600);))
Recent news on Bayer AG
See all newsBayer takes a giant leap toward investability
Europe Research Roundup: Barratt Redrow, Ferrari, KPN
Explainer: What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?
Bayer shares soar over 18% after U.S. Supreme Court curbs Roundup lawsuits
US Supreme Court scales back Roundup cancer suits in win for Bayer (updated)